LEO Pharma A/S: Tralokinumab Achieves Primary and Secondary

Sixteen-week results from the Phase 3 ECZTRA 6 trial in adolescents showed tralokinumab 150 mg and 300 mg significantly improved measures of efficacy compared to placebo1 Tralokinumab was generally

Related Keywords

Illinois , United States , Northwestern University , Canada , Denmark , Chicago , Amy Paller , Kostenloser Wertpapierhandel , Tralokinumab Monotherapy , David Patti , Las Vegas , Product Communications , European Commission , Drug Administration , Department Of Dermatology , Feinberg School Of Medicine , Health Canada , Clinical Dermatology Conference , Feinberg School , Adolescent Subjects With Moderate , Severe Atopic Dermatitis , Pharma , Tralokinumab , Chieves , Primary , Secondary , Endpoints , Hase , Trial , Adolescents , Ith , Moderate , Evere , Topic , Dermatitis ,